Phase 2, Double-Blind, Randomized, Placebo-Controlled Study of the Safety and Efficacy of Elagolix in Women with Polycystic Ovary Syndrome

    February 2023 in “ F&S Reports
    Michael C. Snabes, Juki Ng, Hong Li, Izna Ali, Mohamad Shebley, William D. Schlaff
    Studysummary This study found that elagolix treatment did not normalize the ovulatory cycle in patients with polycystic ovarian syndrome.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Discuss this study in the Community →

    Research cited in this study

    2 / 2 results